Group Leader in Chemical Proteomics, Dr. Guillaume Médard, and his research group in the lab. Image: Uli Benz / TUM
Group Leader in Chemical Proteomics, Dr. Guillaume Médard, and his research group in the lab. Image: Uli Benz / TUM - Mass-spectrometry based proteomics is the big-data science of proteins that allows to monitor the abundances of thousands of proteins in a sample at once. It is therefore a particularly well suited readout to discover which proteins are targeted by any small molecule. An international research team has investigated this using chemical proteomics. Histone deacetylase (HDAC) inhibitors are a class of drugs used in oncology. An international research team involving scientists at the Technical University of Munich (TUM), Cornell University in Ithaca (USA), the German Cancer Research Center (DKFZ) in Heidelberg and Martin Luther University of Halle-Wittenberg has now investigated the effects of some HDAC drugs in more detail. The scientists wanted to know whether those epidrugs engage proteins other than the HDACs which they are designed to inhibit.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
